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Abstract
Motivation: Gene selection has become a common task in most gene expres-
sion studies. The objective of such research is often to identify the smallest possible
set of genes that can still achieve good predictive performance. The problem of
assigning tumours to a known class is a particularly important example that has
received considerable attention in the last ten years. Many of the classification
methods proposed recently require some form of dimension-reduction of the problem.
These methods provide a single model as an output and, in most cases, rely on the
likelihood function in order to achieve variable selection.
Results: We propose a prediction-based objective function that can be tailored
to the requirements of practitioners and can be used to assess and interpret a given
problem. The direct optimization of such a function can be very difficult because the
problem is potentially discontinuous and nonconvex. We therefore propose a general
procedure for variable selection that resembles importance sampling to explore the
feature space. Our proposal compares favorably with competing alternatives when
applied to two cancer data sets in that smaller models are obtained for better or at
least comparable classification errors. Furthermore by providing a set of selected
models instead of a single one, we construct a network of possible models for a
target prediction accuracy level.
Contact: stephane@illinois.edu
? The first two authors are Joint First Authors.
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1 Introduction
Gene selection has become a common task in most gene expression studies. The goal of
this research is often to identify the smallest possible set of genes that can still achieve
good predictive performance (Dı´az-Uriarte and De Andres, 2006). The problem of
assigning tumours to a known class is an example that is of particular importance and
has received considerable attention in the last ten years. Conventional class prediction
methods of leukemia or other cancers are in general based on microscopical examination
of stained tissue specimens. However, such methods require highly trained specialists
and are subjective (Tibshirani et al., 2002).
To avoid these drawbacks, many automatic classification methods have been proposed
recently. These methods have the advantage of being objective and have improved the
correct classification rate in various cases. Among the different methodologies brought
forward in this context we can find those proposed by Tibshirani et al. (2002), Dudoit
et al. (2002), Zhu and Hastie (2004), Zou and Hastie (2005). See also Dı´az-Uriarte and
De Andres (2006) and the references therein for other approaches.
Nonetheless, many of these methods do not necessarily respond to the needs of
practitioners and researchers when they approach the gene selection process. First of all,
many of them have to rely on some form of size reduction and often require a subjective
input to determine the dimension of the problem. Also, many of these methods often
provide a single model as an output whereas genes interact inside biological systems and
can be interchangeable in explaining a specific response. The idea of interchangeability
of genes in explaining responses appears for instance in Kristensen et al. (2012). These
authors use the PARADIGM algorithm of Vaske et al. (2010) to combine mRNA
expression and DNA copy number in order to construct clusters of patients that provide
the best predictive value. The resulting clusters can be seen as being characterized by
different significantly expressed genes.
Another issue of most existing gene selection methods is their reliance on the
likelihood function, or a penalized version of it, as a means to develop a selection
criterion. However, the likelihood function may not necessarily be the quantity that
users are interested in as they may want to target some other kind of loss function such
as, for example, the classification error. Of course, maximizing the likelihood function
is not typically the same as minimizing a particular loss function. Moreover, adapting
these methods to handle missing or contaminated data is not straightforward. This has
limited the applicability and reliability of these methods in many practical cases.
To eliminate the limitations of the gene selection procedures described above, this
paper proposes an objective function for out-of-sample predictions that can be tailored
to the requirements of practitioners and researchers. This is achieved by enabling them
to select a criterion according to which they would like to assess and/or interpret a
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given problem. However, the optimization of such a criterion function is typically not
an easy task since the function can be discontinuous, non-convex and would require
computationally intensive techniques. To tackle this issue, we propose a solution using
a different approach based on a procedure that resembles importance sampling. This
new approach provides a general and flexible framework for gene selection as well as for
other model selection problems.
The advantages of this proposal are multiple:
• Flexibility: It allows the users to specify a criterion that can be tailored to the
specific problem setting. It is able to handle different kinds of responses, problems
of missing and contaminated data, multicollinearity, etc.
• Prediction Power: The result of the procedure is a set of models with high
predictive power with respect to the specified criterion. It is especially suitable in
selecting genes and models to achieve accurate predictions.
• Dimension-reduction: It can provide an assessment of the dimension of the
problem because it greatly reduces the number of necessary covariates and eases
the interpretation without requiring any preliminary size reduction.
• Network-building: With the reduced model size, it preserves the capacity to
build gene-networks to provide a more general view of the potential paradigmatic
structures of the genetic information.
This last aspect is of great interest for gene selection since this list can provide
insight into the complex mechanisms behind different biological phenomena. Different
cases, some of which can be found in Section 4, indicate that this method appears to
outperform other methods in terms of criteria minimization while, at the same time,
selects models of considerably smaller dimension which allow improved interpretation of
the results. The set of selected models can naturally be viewed as a network of possible
structures of genetic information. We call this a paradigmatic network. In Section 4 we
give an example of a graphical representation of such networks based on the analysis of
one of two cancer data sets which are discussed therein.
In this paper we first describe and formalize the proposed approach within the model
selection statistical framework in Section 2. In Section 3 we illustrate the techniques and
algorithms used to address the criterion minimization problem highlighted in Section
2. The performance of our approach is then illustrated on two data sets concerning
leukemia classification (Golub et al., 1999) and breast cancer classification (Chin et al.,
2006) in Section 4. We conclude the paper in Section 5 by summarizing the benefits of
the new approach and providing an outlook on other potential applications that can
benefit from this methodology.
3
2 Approach
To introduce the proposed method, let us first define some notation which will be used
throughout this paper:
1. Let Jf = {1, 2, ..., p} be the set of indices for p potential covariates included in
the n× p matrix X. We allow X to include a vector of 1s.
2. Let J = P(Jf ) \ ∅, |J | = 2p − 1, be the power set including all possible models
that can be constructed with the p covariates excluding the empty set.
3. Let  ∈ J be a model belonging to the above mentioned power set.
4. Let β ∈ Rp be the parameter vector for model , i.e.
βk =
{
βk if k ∈ 
0 if k 6∈ 
where βk, βk are respectively the kth element of β
 and β.
Keeping this notation in mind, for a given model  ∈ J we have
Y = g(X,β) + ε, (1)
where g(·, ·) is a link function known up to the parameter vector β ∈ Rp and ε is a mean
zero random error. Models of the form (1) are very general and include all parametric
models and a large class of semiparametric models when g(·, ·) is not completely known
or the distribution of ε is not specified. A few examples of model (1) are given in
Appendix A.
We assume that for a fixed , based on a specific choice for model (1) with cor-
responding parameter vector β and given a new covariate vector X0, the user can
construct a prediction Ŷ (X0,β
). To assess the quality of this prediction we assume
that we have a divergence measure available which we denote as D{Ŷ (X0,β), Y0}. The
only requirement imposed on the divergence measure is that it satisfies the property of
positiveness, i.e.
D(u, v) > 0 for u 6= v
D(u, v) = 0 for u = v.
With this property being respected, the divergence measure can arbitrarily be specified
by the user according to the interest in the problem. Examples of such divergence
measures include the L1 loss function
D{Ŷ (X0,β), Y0} = |Ŷ (X0,β)− Y0|
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or an asymmetric classification error
D{Ŷ (X0,β), Y0} =I{Ŷ (X0,β) = 1, Y0 = 0}w1
+I{Ŷ (X0,β) = 0, Y0 = 1}w2.
where w1, w2 ≥ 0. The latter is for a Bernoulli response and is typically an interesting
divergence measure when asymmetric classification errors have to be considered. Indeed,
in most clinical situations, the consequences of classification errors are not equivalent
with respect to the direction of the misclassification. For instance, the prognosis and the
treatment of Estrogen Receptor (ER) positive Breast Cancers (BC) are quite different
from thoe of ER negative ones. Indeed, if a patient with ER negative is treated with
therapies designed for patients with ER positive, the consequence is much more severe
than if this were done the other way round because of the excessive toxicities and
potentially severe side effects. It therefore makes sense to give different values to w1
and w2. By defining w1 > w2 we would take these risks into account, where w1 would
be the weight for a misclassification from ER negative to ER positive BC and w2 for the
opposite direction. Weight values can be modulated according to the current medical
knowledge and the clinical intuition of the physicians.
Considering this divergence measure D(·, ·), we are consequently interested in finding
the best models within the general class given in (1). To do so, we would ideally aim at
solving the following risk minimization problem :
β̂
 ∈ B ≡ argmin
∈J
argmin
β
E0
[
D
{
Ŷ (X0,β
), Y0
}]
, (2)
where E0 denotes the expectation on the new observation (Y0,X0). Let 0 denote the
models with the smallest cardinality among all β̂
 ∈ B. Note that there could be more
than one model with the same prediction property and of the same size, hence 0 could
contain more than one model. Let us define the models corresponding to 0 as the “true”
models. Thus, our “true” models are essentially the most parsimonious models that
minimize the expected prediction error.
The optimization problem in (2) is typically very difficult to solve. First of all,
supposing we do not consider interaction terms, the outer minimization would require
to compare a total of 2p − 1 results, each a result of the inner minimization problem.
In addition, each of the 2p − 1 inner minimization problems is also very hard to solve,
even if the risk E0[D{Ŷ (X0,β), Y0}] were a known function of β. Indeed, the inner
minimization problem is in general non-convex and could be combinatorial, implying
that the minimizer might not be unique. For example, when D(·, ·) is the classification
error, this problem is combinatorial by nature. In practice, the computational challenge
is even greater because the risk function E0[D{Ŷ (X0,β), Y0}] is a function of βJ
without explicit form and needs to be approximated.
We propose to estimate E0[D{Ŷ (X0,β), Y0}] via an m-fold cross-validation (typi-
cally m = 10) repeated K times. More specifically, for a sample of size n, we repeat
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the following procedure K times. At the kth repetition, we randomly select bn/mc
observations to form a “test” data set, subindexed i = 1, . . . , bn/mc and superindexed
k = 1, . . . ,K, i.e. (Xki , Y
k
i ), then the estimated risk is
Ê0
[
D
{
Ŷ (X0,β
), Y0
}]
=
1
bn/mcK
K∑
k=1
bn/mc∑
i=1
D{Ŷ (Xki ,β), Y ki }. (3)
The reason we only use bn/mc observations out of the whole data set will become clear
further on. Having approximated the expectation E0, the minimization problem in (2)
becomes
argmin
∈J
argmin
β
Ê0
[
D
{
Ŷ (X0,β
), Y0
}]
. (4)
Despite the above approximation, the minimization problem remains complicated for the
reasons mentioned earlier. Thus, we further eliminate the inner minimization problem
in (4) by inserting an estimator β̂

obtained independently from the minimization
procedure. More specifically, we assume that an estimator of β, say β̂
,k
, is available
based on model (1) and “training” observations (Xkbn/mc+1, Y
k
bn/mc+1), . . . , (X
k
n, Y
k
n ) (i.e.
those observations excluded from the above mentioned “test” data sets). This estimator
can be any available estimator, for example, the maximum likelihood estimator (MLE), a
moment based estimator, or a quantile regression based estimator, etc. We then replace
the inner minimization in (4) directly with the approximate expectation evaluated at
β̂
,k
’s and simplify (4) to
argmin
∈J
1
bn/mcK
K∑
k=1
bn/mc∑
i=1
D
{
Ŷ (Xki , β̂
,k
), Y ki
}
.
The intuition of replacing the inner minimization in (4) with a sample average evaluated
at an arbitrary estimator is due to the fact that this estimator, under a fixed “true”
model and regardless of whether this estimator is a standard MLE or a minimizer
of the divergence measure D, is an approximation to the “true” parameter. This
means that, consequently, different estimators are “close” to each other. As a con-
sequence, (bn/mcK)−1∑Kk=1∑bn/mci=1 D{Ŷ (Xki , β̂,k), Y ki } is a close approximation to
minβ E0
[
D
{
Ŷ (X0,β
), Y0
}]
.
We now have an optimization problem in (2) which requires a comparison of 2p − 1
values and is much easier to solve. To further reduce the number of comparisons,
the following section describes some procedures and algorithms allowing to solve this
problem in a more efficient manner.
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3 Heuristic procedure
To solve the optimization problem in (2), we propose an approach designed to have the
following three features:
1. Identify a set of models that carry large predictive power instead of a single
“best” model;
2. Find this set of models within a reasonable time, without having to explore all
possible models;
3. This set achieves sparsity, i.e. most of the parameters in β will be fixed at zero
in each of the models in the set.
Note that the last feature above reflects the belief that most of the covariates are
irrelevant for the problem under consideration and should be excluded. Indeed, our
method is designed to work effectively if such a sparsity assumption holds, putting it
on the same level of almost all variable selection procedures in the literature. Moreover,
we require the method to have the first feature in order to increase flexibility in terms
of interpretation. Indeed, in many domains such as gene selection, for example, the aim
may not be to find a single model but a set of variables (genes) that can be inserted
in a paradigmatic structure to better understand the contribution of each of them via
their interactions.
Given this goal, assume that we have at our disposal an estimate of the measure
of interest D(·, ·) for all possible 2p − 1 models. In this case, our interest would be
to select a set of “best” models by simply keeping the set of models that have a low
discrepancy measure D(·, ·). It is of course unrealistic to obtain a discrepancy measure
for all models in most practical cases because this would require a considerable amount
of time for computation. Therefore, in order to achieve the second feature, instead of
examining all possible models, we can randomly sample covariates from J . The random
sampling needs to be carefully devised because in practice, for example in gene selection
problems, the number of covariates p can easily reach thousands or tens of thousands
(see examples in Section 4, where p = 7, 129 and p = 22, 215 respectively). In such
situations, 2p−1 is an extremely large number and the probability of randomly sampling
a “good” set of variables from the 2p − 1 variables is very small. Using the sparsity
property of the problem, we propose to start with the set of variables M0 (typically an
empty set) and increase the model complexity stepwise. Throughout this procedure,
we ensure that at step k, the more promising covariates based on the evaluation at
step k − 1 are given higher probabilities of being randomly drawn. The last idea is in
the spirit of “importance sampling” in the sense that covariates with more importance
based on the previous step are “encouraged” to be selected in the current step. Note
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that by construction we achieve sparsity if we stop the stepwise search at models of size
dmax  p.
More formally, let us first define the set of all possible models of size d as
Sd = {(i1, . . . , id) | i1, . . . , id ∈ Jf ; i1 < . . . < id}.
We then define the set of promising models, S∗d , as the ones with an estimated out-of-
sample divergence measure D(·, ·) below a certain estimated α-quantile. The value of α
is user-defined depending on the problem at hand, and is typically a small value such
as α = 1%. The formal definition of this set would then be
S∗d = { |  ∈ Sd ; D̂ ≤ q̂d(α)},
where
D̂ ≡ 1bn/mcK
K∑
k=1
bn/mc∑
i=1
D{Ŷ (Xki , β̂
,k
), Y ki }, (5)
and q̂d(α) is the α-quantile of the D̂ ( ∈ Sd) values issued from the B randomly
selected models. Finally, we define the set of indices of covariates that are in S∗d as
I∗d = {i | i ∈ ,  ∈ S∗d}
whose complement we define as Icd (i.e. all those covariates that are not included in I∗d).
With this approach in mind and using the above notations, to start the procedure
we assume that we have p variables from which to select.
A. Initial Step: We start by adding the number of variables d = 1 to our initial
variable set M0 with the goal of finally obtaining the set I∗1 .
1. Construct the p possible one variable models by augmenting M0 with each
of the p available variables.
2. Compute D̂ for every model obtained in Step A.1.
3. From Steps A.1 and A.2, construct the set I∗1 using (3). Go to Step B and
let d = 2.
B. General Step: We define here the general procedure to construct I∗d for 2 ≤ d ≤
dmax.
1. Augment M0 with d variables as follows:
(i) Randomly select a set, either set I∗d−1 with probability pi or its comple-
ment Icd−1 with probability 1− pi.
(ii) Select one variable uniformly at random and without replacement from
the set chosen in Step (i) and add this variable to M0.
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(iii) Repeat Steps (i) and (ii) until d variables are added to M0.
2. Construct a model of dimension d using the d variables selected in Step B.1.
Repeat Step B.1 B times to construct B such models.
3. From Steps B.1 and B.2, construct the set I∗d according to (3). If d < dmax,
go to Step B and let d = d+ 1, otherwise exit algorithm.
3.1 Discussion
Some ideas that our approach and our algorithm use can be found in the literature. We
relegate a short discussion of these to Appendix D. Here we will discuss instead some
practical issues arising when implementing our algorithm.
3.1.1 Choice of algorithm inputs:
The parameters dmax, B, α and pi of the above algorithm are to be fixed by the user. As
mentioned earlier dmax represents a reasonable upper bound for the model dimension
which is constrained to dmax ≤ l, where l depends on the limitations of the estimation
method and is commonly the sample size n. As for the parameter B, a larger value is
always preferable to better explore the covariate space. However, a larger B implies
heavier computations, hence a rule of thumb that could be used is to choose this
parameter such that p ≤ B ≤ (p2). As mentioned earlier, the parameter α should define
a small quantile, typically 1%. Finally, pi determines to what extent the user assigns
importance to the variables selected at the previous step. Given that dmax  p and α
is small, we will typically have that |I∗d−1| < |Icd−1|. In this setting, a choice of pi = .5
for example would deliver a higher probability for the variables in I∗d−1 to be included
in I∗d . All other parameters being equal, increasing the value of pi would decrease the
probability of choosing a variable in Icd−1 and vice versa. Moreover, we discuss in
Appendix B how the proposed algorithm can be adjusted to situations where p is either
small or very large.
As a final note, it is also possible for the initial model M0 to already contain a set
of p0 covariates which the user considers to be essential for the final output. In this
case, the procedure described above would remain exactly the same since the procedure
would simply select from the p covariates which are not in the user-defined set and the
final model dimension would simply be p0 + d.
3.1.2 Algorithm output:
Once the algorithm is implemented, the user obtains an out-of-sample discrepancy
measure for all evaluated models. The final goal is then to find a subset of models
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of dimension d∗ that in some way minimize the considered discrepancy. A possible
solution would be to select the set of models S∗d∗ such that d∗ = min∈{1,...,dmax} qd(α).
However, the quantity qd(α) is unknown and replaced by its estimator q̂d(α). Due to
this, a solution that might be more appropriate would be to consider a testing procedure
to obtain d∗ taking into account the variability of q̂d(α). For example, we could find the
dimension d∗ such that we cannot reject the hypothesis that q̂d∗(α) = q̂d∗+1(α). Thus
we sequentially test whether q̂j+1 is smaller than q̂j for j = 1, . . . , dmax. As long as the
difference is significant we increment j by one unit, otherwise the minimum is reached
and d∗ = j. A more detailed discussion on the type of tests that can be used for this
purpose is presented in Appendix C.
4 Case Studies
In this section we provide an example of how the methodology proposed in this paper
selects and groups genes to explain, describe and predict specific outcomes. We focus
on the data-set (hereinafter leukemia) which collects information on Acute Myeloid
Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) and is frequently used
as an example for gene selection procedures. Indeed, Golub et al. (1999) were among
the first to use this data to propose a gene selection procedure which was then followed
up by other proposals that used the same data to compare their performance. We will
use this data-set to underline the features and advantages of the proposed method.
A second data-set concerning the research on breast cancer (presented in Chin et al.
(2006)) is analysed in Appendix F to show the outputs of the proposed method from
another example.
The analysis of these data-sets focuses both on the advantages of the proposed
methodology and the biological interpretation of the outcomes. One of the goals of
our method is to help decipher the complexity of biological systems. We will take
on an overly simplified view of the cellular processes in which we will assume that
one biomarker maps to only one gene that in turn has only one function. Although
this assumption is not realistic, it allows us to give a straightforward interpretation of
the selected models or “networks” which can therefore provide an approximate first
insight into the relationships between variables and biomarkers (as well as between
the biomarkers themselves). We clarify that we do not claim any causal nature in the
conclusions we present in these analyses but we believe that the selected covariates can
eventually be strongly linked to other covariates that may have a more obvious and
direct interpretation for the problem at hand. Finally, the data-set has binary outcomes
(as does the data-set in Appendix F), hence we will make use of the Classification Error
(CE) as a measure of prediction performance and we will not assign weights to a given
prediction error. This means that misclassification errors are given the same weight,
in the sense that a false positive prediction (e.g. predicted “presence” when the truth
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is “absence”) is considered as undesirable as a false negative prediction. However, our
method can consider also divergence measures based on unequal weights as highlighted
in Section 2.
4.1 Acute Leukemia
4.1.1 Statistical analysis
Golub et al. (1999) were among the first to propose an automatic selection method for
cancer classification and demonstrated the advantages of using such a method. One of
the main applications of their method was on the leukemia data-set in which information
regarding 72 patients is included, namely their type of leukemia (25 patients with AML
and 47 patients with ALL) and 7,129 gene expressions used as explanatory variables to
distinguish between two types of leukemia. As explained in Golub et al. (1999) this
distinction is critical for successful treatment which substantially differs between classes.
In fact, although remissions can be achieved using any of these therapies, cure rates are
markedly increased and unwarranted toxicities are avoided when targeting the specific
type of leukemia with the right therapy.
In order to understand how our proposed methodology performs compared to
existing ones, we split the leukemia data into the same training set (38 patients) and
test set (34 patients) as in the original work by Golub et al. (1999). We employ our
method on the training set to understand the dimension of the model and to select
the most relevant genes. Setting α = 0.01, the corresponding observed quantile of the
10-fold cross-validation CE (D̂) is shown in Figure 1. It can be seen that the error
immediately decreases to almost zero when using two covariates instead of one, after
which it monotonically increases, suggesting that the optimal model dimension is two.
In Figure 1 we also plotted the performance of the other selection methods used
on this training data which are represented by labelled dots reporting the acronyms of
these methods that are listed in Table 1. The approach proposed in this work compares
favourably to all other methods in terms of prediction power. Indeed, all the other
methods lie under the curve to the right of its minimum indicating that, compared to
our method, they select models of considerably higher dimensions without achieving
the same degree of performance in terms of CE. Therefore, for this particular case,
our method outperforms the other methods. The sparsity and tenfold CV error are
further illustrated in Table 1, where we also present the average prediction error on the
test data. Considering the latter, it can be seen how the performance of the different
methods are similar but the proposed method is able to achieve the same performance
by selecting models of a considerably lower dimension. As a final note to the table,
the last line reports the performance of model averaging. Indeed if the interest lies in
predicting, as described earlier, the algorithm of Section 3 provides a set of models
11
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Figure 1: Number of covariates vs. D̂ on leukemia cancer classification training set. The
names are abbreviations for other selection method referred in Table 1.
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whose CE is below a given quantile α. The predictions of these models can be used in
the spirit of model averaging where a general prediction can be obtained by taking the
average of predictions of the selected set of models. The proposed methodology can
therefore be potentially seen as a bridge between model selection and model averaging.
Method Tenfold CV Test error Number of
error genes
Golub 3/38 4/34 50
Support vector machine 2/38 1/34 31
(with recursive feature elimination)
Penalised logistic regression 2/38 1/34 26
(with recursive feature elimination)
Nearest shrunken centroids 2/38 2/34 21
Elastic net 3/38 0/34 45
Proposed
Model a 0/38 2/34 2
Model b 0/38 2/34 2
Model c 0/38 2/34 2
[. . .]
Model averaging 2/34 2
Table 1: Summary of Leukemia classification results. The table is taken from Zou and Hastie
(2005) except for the Proposed part. We obtained a total of 107 models of size 2 (109 different
biomarker) using a probability α = 0.01, B = 20000 bootstrap replicates, a selection probability
pi = .5 with D the tenfold-CV repeated 10 times. Model a to c are three examples out of the 107
models. All 107 models have a tenfold-CV error of 0. The best test error is 2 and the worst is
12. For model averaging all models are equally weighted.
Once this procedure is completed, we can create a gene network to facilitate in-
terpretation. This is a direct benefit of our method which does not deliver a single
model after the selection process but provides a series of models that can be linked
to each other and interpreted jointly. Indeed, the existence of a single model that
links the covariates to the explained variable is probably not realistic in many settings,
especially for gene classification. For this reason, the frequency with which each gene
is included within the selected models and with which these genes are coupled with
other genes provides the building block to create an easy-to-interpret gene network with
powerful explanatory and predictive capacities. A graphical representation of this gene
network can be found in Appendix E together with a table where the biomarkers are
listed according to their position in the model. These positions represent families of
biomarkers (or genes) whose members are interchangeable. By the latter we mean that,
given the presence of biomarkers from other families, specific biomarkers can be replaced
by another biomarker from within the same family without losing predictive power.
This is the idea behind finding a paradigmatic network for gene selection purposes. In
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the following paragraph we provide a summary biological interpretation of the the three
main biomarkers (i.e. the most frequent in the selected models) which we call “hubs”
from which the networks start.
4.1.2 Biological interpretation
The three hubs that were identified are the following:
1. Cystatin C: a secreted cysteine protease inhibitor abundantly expressed in body
fluids (see Xu et al., 2015);
2. Zyxin: a zinc-binding phosphoprotein that concentrates at focal adhesions and
along the actin cytoskeleton;
3. Complement factor D: a rate-limiting enzyme in the alternative pathway of
complement activation (see White et al., 1992).
In the current state of knowledge about acute leukemia, these three hubs appear
to make sense from a biological viewpoint. Cystatin C is directly linked to many
pathologic processes through various mechanisms and recent studies indicate that
the roles of Cystatin C in neuronal cell apoptosis induction include decreasing B-cell
leukemia-2 (BCL-2) whose deregulation is known to be implicated in resistant AML (see
Sakamoto et al., 2015). Zyxin is a protein that interacts with Vasodilator-stimulated
phosphoprotein (VASP) with both being involved in cellular adhesion and motility.
VASP interacts with ABL (breakpoint cluster region-abelson) and is a substrate of the
BcrAbl oncoprotein which drives oncogenesis in patients with chronic myeloid leukemia
(CML) due to a constitutive activation of tyrosine kinase activity (see Bernusso et al.,
2015). Further results suggest that the phosphorylation and dephosphorylation cycle
of VASP by the Abi-1-bridged mechanism regulates association of VASP with focal
adhesions, which may regulate adhesion of Bcr-Abl-transformed leukaemic cells (see
Masahiro et al., 2012). Finally, Complement factor D, together with several other
components of both the classical and alternative complement cascade, is primarily
expressed through both adipocytes and monocytes-macrophages in human subjects (see
White et al., 1992; Gabrielsson et al., 2003). A recent review in Ratajczak (2014) has
stressed the role of the complement cascade as a trigger for hematopoietic stem cells
from bone marrow into blood.
The interpretation of the network can be carried out through plots or tables such
as those presented in Appendix E where the biomarkers can be grouped together
into clusters having the same biological traits, e.g. transcription/translation factor
activity, DNA repair and catabolism, apoptotic activity. This grouping allows a
more straightforward interpretation of the links between the different families thereby
providing a more general overview of how the elements of the identified network interact.
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5 Conclusions
This paper has proposed a new model selection method with various advantages com-
pared to existing approaches. Firstly, it allows the user to specify the criterion according
to which they would like to assess the quality of a model. In this setting, it gives an
estimate of the dimension of the problem, allowing the user to understand how many
gene expressions are needed in a model to well describe and predict the response of
interest. Building on this, it provides a paradigmatic structure of the selected models
where the selected covariates are considered as elements in an interconnected biological
network. The approach can handle more variables than observations without going
through dimension-reduction techniques such as pre-screening or penalization.
The problem definition of this method and the algorithmic structure used to solve it
deliver further advantages such as the ability to cope with noisy inputs, missing data,
multicollinearity and the capacity to deal with outliers within the response and the
explanatory variables (robustness).
Some issues which must be taken into account concerning the proposed method are
(i) its computational demand and (ii) its need for an external validation. As far as the
first aspect goes, this can be considered indeed negligible compared to the time often
required to collect the data it should analyse and can be greatly reduced according
to the needs and requirements of the user. Concerning the second aspect, external
validation is a crucial point which is often overlooked and is required for any model
selection procedure. In this sense, the proposed method does not differ from any other
existing approach in terms of additional requirements.
Having proposed a method with considerable advantages for gene selection using
statistical ideas in model selection and machine learning, we expect future research
concerning the statistical properties of this approach aiming at understanding its
asymptotic behaviour and developing inference tools, which will be highly challenging
and rewarding.
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A Example for Model (1)
A few examples of model (1) are as follows:
• Y can be a continuous variable representing, for example, the concentration of a
certain substance in the body. In this case, a common model is Y = XTβ + ,
which corresponds to g(X,β) = XTβ.
• Y can also be a count variable, such as when it represents the number of tumours
in a patient. A common Poisson model is
P(Y = y | X) = exp(−eXTβ)eXTβy/y!,
which can be equivalently written as Y = eX
Tβ+, where  = exp(−eXTβ)eXTβY /Y !−
eX
Tβ has mean zero and g(X,β) = eX
Tβ .
• Y can be a Bernoulli random variable (Y ∈ {0, 1}), when it records the pres-
ence/absence of a tumour. A common logistic model is
P(Y = 1 | X) = 1− 1/(eXTβ + 1)
and can be equivalently written as Y = 1 − 1/(eXTβ + 1) + , where  =
Y − 1 + 1/(eXTβ + 1) also has mean zero. Thus g(X,β) = 1− 1/(eXTβ + 1).
B Adapting the algorithm to p
In this subsection we provide two variants of the algorithm proposed in Section 3 in
order to adapt it to situations where p is either small or large.
B.1 Adapting the algorithm to very large p
In situations where p is extremely large and the initial step of the algorithm is not
computationally feasible, this step can, for example, be replaced by the following
modified initial step:
A′. Large p Modified Initial Step: We start by augmenting our initial variable set M0
with d = 1 variable in order to construct the set I∗1 .
1. Augment M0 with d = 1 variable selected uniformly at random in Jf .
2. Construct B models of dimension 1 by repeating Step A′.1 B times.
3. From Steps A′.1 and A′.2, construct the set I∗1 using (3). Go to Step B and
let d = 2.
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B.2 Adapting the algorithm to small p
On the other hand, when p is of reasonable size it may be possible to compute and
evaluate all the
(
p
d′
)
models of dimension 2 ≤ d′ ≤ dmax. In such cases, it may be feasible
to also modify the initial step of the proposed algorithm to a different modified initial
step. A possible modification is the following:
A′′. Small p Modified Initial Step: We start by augmenting our initial varable set M0
with d (1 ≤ d ≤ d′) variables in order to construct the sets I∗1 , ..., I∗d′ .
1. We augment our initial variable set M0 with 1 variable in order to construct
the set I∗1 .
(i) Construct the p possible models obtained by augmenting M0 with each
of the p available variables.
(ii) Compute D̂(·, ·) for every model obtained in Step (i).
(iii) From Steps (i) and (ii), construct the set I∗1 using (3). Go to Step A′′.2
and let d = 2.
2. We augment our initial model M0 set by d variables in order to construct
the set I∗d .
(i) Construct the
(
p
d
)
possible models and augment M0 with all variables
of these constructed models.
(ii) Compute D̂ for every model obtained in Step (i).
(iii) From Steps (i) and (ii), construct the set I∗d using (3) and let d = d+ 1.
Go to Step A′′.2 (if d < d′) or Step B.1 (if d ≥ d′), with model dimension
starting value d.
C Determining the Models Dimension via Testing
The type of test and its corresponding rejection level are determined by the user based
on the nature of the divergence measure. For example, if we take the L1 loss function
as a divergence, one could opt for the Mann-Whitney test or if the loss function is a
classification error (as in the applications in Section 4), one could choose the binomial
test or other tests for proportions. The rejection level will depend, among others, on
the number of tests that need to be run, typically less than dmax − 1, and need to be
adjusted using, for example, the Bonferroni correction. Finally, once the set S∗d∗ is
obtained, the user may still want to “filter” the resulting models. Indeed, the number of
models in the solution S∗d∗ may be large and the corresponding divergence estimates may
vary considerably from model to model. Since these divergence measures are estimators,
we again propose a multiple testing procedure to reduce the number of models in S∗d∗ .
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Before doing so, we eliminate redundant models, thereby making sure that every model
is included only once. Then, we start the testing procedure with an empty set S0d∗ = ∅
to which we add the model (or one of the models) that has the minimum divergence
measure estimate, denoted D̂min , where min ∈ S∗d∗ denotes this model. Then for every
model  ∈ S∗d∗\min, we test whether D̂ is greater than D̂min . We add the model to
S0d∗ if the difference is not significant and stop adding models as soon as the test deems
that the divergence of the next model is indeed larger. By doing so we finally obtain
S0d∗ ⊆ S∗d∗ which is the set containing the models (and hence covariates) which can be
interpreted in a paradigmatic network.
D Related literature
Some of the ideas put forth in this work have also been considered in the literature. An
extensive survey of the related works goes beyond the scope of this paper. Here we
briefly describe some of the connections to three main ideas that have been explored
previously.
The first one is recognizing that practitioners might aim to minimize some criterion
that differs from likelihood-type losses. An interesting paper illustrating this point is
Juang et al. (1997) in the context of speech recognition. For their classification problem,
these authors propose to minimize a “smoothed” version of the decision rule used for
classification. The advantage of this procedure is that it yields better misclassification
errors than using pure likelihood based criteria which intrinsically fit a distribution
to the data. In the approach presented in this work we also deliver an approximate
solution but, as opposed to approximating the problem and solving the latter in an exact
manner as in Juang et al. (1997), we define the exact problem and try to approximately
minimize the misclassification error through our algorithm.
Second, there is a large literature that uses stochastic search procedures to explore
the space of candidate models. Influential work in this direction include George and
McCulloch (1993) and George and McCulloch (1997) who postulate hierarchical Bayesian
models. In their set up, subsets of promising predictors form models with higher posterior
probabilities. An interesting application of this framework for disease classification using
gene expression data is the work of Yang and Song (2010). Cantoni et al. (2007) also
consider a random exploration of the space of possible models, but avoiding the Bayesian
formulation of George and McCulloch (1993). Their approach defines a probability
distribution for the various candidate models based on a cross-validated prediction error
criterion and then uses a Markov Chain Monte-Carlo method to generate a sample from
this probability distribution. An important feature of the stochastic search implied
by our algorithm is that it is a greedy method, while the aforementioned methods are
not. The typical forward/backward greedy algorithms proposed in the literature are not
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random, while existing stochastic procedures are not greedy. Thus, the combination of
greedy approach and random search approach seems to be new. See for instance Zhang
(2011) for some theory on greedy algorithms in sparse scenarios.
Third, other authors have also considered providing a set of interesting models as
opposed to a single “best” model. The stochastic search procedures mentioned in the
above paragraph can naturally be used to obtain a group of interesting models. For
example, Cantoni et al. (2007) consider a set of best indistinguishable models in terms of
prediction. Random forests can be used to select variables and account for the stability
of the chosen model as in Dı´az-Uriarte and De Andres (2006). These methods can also
be used to construct a set of interesting models.
E More results on Acute Leukemia
Figure 2 graphically represents the network created by the proposed method for the
leukemia data-set where the size of a disk represents the frequency with which a
particular biomarker is included in the selected models, and the line connecting the
disks indicates the biomarkers that are included in the same model. Since the model
dimension in this case is two, each biomarker is connected with only one other biomarker
and, as can be observed, the proposed method identifies three main “hubs” for the
networks (green disks) generating three networks.
Table 2 reports the main biomarker hubs and related biomarker networks for the
leukemia data set analysed in Section 4.1.
F Breast Cancer
The second data-set we analyzde is the breast cancer data presented in Chin et al. (2006)
for which we only provide a summary biological interpretation of the results of the
proposed method, having already discussed the working of our approach in Section 4.1.
The main goal behind analyzing this data is to identify the estrogen receptor expression
on tumor cells which is a crucial step for the correct management of breast cancer.
Figure 3 shows the paradigmatic network identified by our method for the breast cancer
data for which the selected model dimension is three (i.e. only three biomarkers are
needed in a model to well classify the breast cancer). Table 3 provides the details of the
networks based on the three main hubs and is to be interpreted as described in Section
4.1.
This figure is a clear example of the advantages of the proposed method since, it
not only selects a set of low-dimensional models with a high predictive power, but also
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Figure 2: Network representation of biomarkers selected from leukemia data-set. Colors
represent the position of covariates within the model: green for first position (hub) and orange
for second. The width of the connecting lines is proportional to the frequency with which two
biomarkers appear in the same model. The size of the disk is proportional to the frequency with
which a biomarker is present within the selected set of models.
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Figure 3: Network representation of biomarkers selected from breast cancer data-set. Colors
represent the position of covariates within the model: green for first position (hub), orange for
second and purple for third. The width of the connecting lines is proportional to the frequency
with which two biomarkers appear in the same model. The size of the circles is proportional
to the frequency with which a biomarker is present within the selected set of models. (Note:
biomarker “209602 s at” is merged with biomarker “209604 s at”).
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Affy ID Gene ID Gene Function Biological
Process
NETWORK 1
Position 1 M27891 at ENSG00000101439 Cystatin C AA
Position 2 D80006 at ENSG00000114978 MOB kinase activator 1A AA
M20778 s at ENSG00000163359 Collagen, type VI, alpha 3 AA
U57316 at ENSG00000108773 K(lysine) acetyltransferase 2A TF
U90549 at ENSG00000182952 High mobility group nucleosomal binding domain 4 TF
X66899 at ENSG00000182944 Ewing Sarcoma region 1; RNA binding protein TF
M74088 s at ENSG00000134982 Adenomatous polyposis coli, DP2, DP3, PPP1R46 TF
U51166 at ENSG00000139372 thymine-DNA glycosylase TF
Z69881 at ENSG00000074370 ATPase, Ca++ transporting, ubiquitous IPT
U49248 at ENSG00000023839 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 IPT
X89109 s at ENSG00000102879 Coronin, actin binding protein, 1A IPT
HG2815-HT2931 at ENSG00000092841 Myosin, Light Chain, Alkali, Smooth Muscle (Gb:U02629) ACC
M94345 at ENSG00000042493 Capping protein (actin filament), gelsolin-like ACC
L33075 at ENSG00000140575 IQ motif containing GTPase activating protein 1 ACC
L07633 at ENSG00000092010 Proteasome (prosome, macropain) activator subunit 1 (PA28 alpha) APC
J03589 at ENSG00000102178 Ubiquitin-like 4A APC
D83920 at ENSG00000085265 FCN1, Ficolin-1 IR
X03934 at ENSG00000167286 CD3d molecule, delta (CD3-TCR complex) IR
NETWORK 2
Position 1 X95735 at ENSG00000159840 Zyxin ACC
Position 2 X04526 at ENSG00000185838 Guanine nucleotide binding protein (G protein), beta polypeptide 1 ST
D78577 s at ENSG00000128245 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase ST
activation protein, eta
U32645 at ENSG00000102034 E74-like factor 4 (ets domain transcription factor) TF
U93867 at ENSG00000186141 Polymerase (RNA) III (DNA directed) polypeptide C (62kD) TF
U29175 at ENSG00000127616 SWI/SNF related, matrix associated, actin dependent regu-
lator of chromatin, subfamily A, member 4
TF
Y00291 at ENSG00000077092 Retinoic acid receptor, beta TF
D17532 at ENSG00000110367 DEAD (Asp-Glu-Ala-Asp) Box Helicase 6 TF
HG3521-HT3715 at ENSG00000127314 Ras-Related Protein Rap1b TF
M83233 at ENSG00000140262 Transcription factor 12 TF
U94855 at ENSG00000175390 Eukaryotic translation initiation factor 3, subunit F TF
L07758 at ENSG00000136045 PWP1 homolog TF
D63506 at ENSG00000116266 Syntaxin binding protein 3 IR
M33680 at ENSG00000110651 CD81 molecule IR
HG1612-HT1612 at ENSG00000175130 Macmarcks CG
M92287 at ENSG00000112576 Cyclin D3 CG
M60483 rna1 s at ENSG00000113575 Protein Phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform CG
U84388 at ENSG00000169372 CASP2 and RIPK1 domain containing adaptor with death domain AA
S80437 s at ENSG00000169710 Fatty acid synthase
NETWORK 3
Position 1 M84526 at ENSG00000197766 Complement factor D (adipsin) IR
Position 2 M28130 rna1 s at ENSG00000169429 Interleukine-8 IR
Z32765 at ENSG00000135218 CD36 - Thrombospondin receptor IR
Table 2: Biomarker network organisation - leukemia data set - Lymphoblastic / Myeloblastic
leukemia. TF = Transcription/translation factor activity, DNA repair and catabolism - AA
= apoptotic activity - IR = immunity, inflammatory response (blood coagulation, antigen
presentation and complement activation) - IPT = intracellular protein trafficking, transmembrane
transport - ACC = actin activity, cytoskeleton organisation - APC = protein catabolism - ST
= intracelular signal transduction - CG = cell growth, proliferation and division. Source:
www. ensembl. org ; www. uniprot. org
provides the basis for a more general biological interpretation which takes into account
interactions between different biomarkers as opposed to one single model. The three
main hubs identified through the proposed algorithm are:
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1. GATA binding protein 3 (GATA3): a transcription factor regulating the differen-
tiation of breast luminal epithelial cells;
2. IL6 Signal Transducer (IL6 ST): a pro-inflammatory cytokine signal transducer;
3. TBC1 domain family, member 9 (TBC1D9): a GTPase-activating protein for Rab
family protein involved in the expression of the ER in breast tumors.
GATA3 is known to regulate the differentiation of epithelial cells in mammary glands
(see Kouros-Mehr et al., 2006) and is required for luminal epithelial cell differentiation.
Its expression is progressively lost during luminal breast cancer progression as cancer
cells acquire a stem cell-like phenotype (see Chou et al., 2010). IL6 ST has been linked
to breast cancer epithelial-mesenchymal transition and cancer stem cell traits (see
Chung et al., 2014), cancer-promoting microenvironment (see Bohrer et al., 2014) and
resistance (see Christer et al., 2013). Moreover, this result supports the assertion by
Taniguchi and Karin (2014) that IL6 ST and related cytokines are the critical lynchpins
between inflammation and cancer. Finally, concerning the third biomarker, a recent
publication by Andres and Wittliff (2012) has shown that the expression of the ER on
the surface of breast tumor cells is highly correlated with the coordinate expression of
different genes among which we can find TBC1D9 and GATA3. These two genes are
not only considered as relevant genes according to the proposed method but as actual
hubs of the “best” models which define the structure of the identified network. Instead
of selecting a single model with many biomarkers whose interactions may be difficult to
interpret, the proposed method selects a set of models with few biomarkers that allow
them to be individually easy to interpret without losing the possibility of interpreting
them within the larger network. This is what this paper intends with the expression
“paradigmatic network” since by taking this approach it is possible to identify a set of
biomarker families within which each biomarker is interchangeable with the others.
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Affy ID Gene ID Gene Function Biological
Process
NETWORK 1
Position 1 209604 s at ENSG00000107485 GATA binding protein 3 TF
Position 2 205520 at ENSG00000115808 Striatin, calmodulin binding protein ER
Position 3 204902 s at ENSG00000168397 Autophagy related 4B, cysteine pepti-
dase (APG4B, AUTL1, DKFZp586D1822,
KIAA0943)
APC
221698 s at ENSG00000172243 C-type lectin domain family 7, member A IR
49049 at ENSG00000178498 Deltex 3, E3 ubiquitin ligase APC
209602 s at ENSG00000107485 GATA binding protein 3 TF
216604 s at ENSG00000003989 Solute carrier family 7 (cationic amino acid
transporter, y+ system), member 2
IPT
218877 s at ENSG00000066651 TRNA methyltransferase 11 homolog TF
201316 at ENSG00000106588 Proteasome (prosome, macropain) subunit,
alpha type, 2
APC
Position 2 208019 at ENSG00000147117 Zinc finger protein 157 TF
Position 3 219168 s at ENSG00000186654 PRR5 (Proline rich 5 (renal)) CG
219493 at ENSG00000171241 SHC SH2-domain binding protein 1 CG
204590 x at ENSG00000139719 Vacuolar protein sorting 33 homolog A APC
210021 s at ENSG00000152669 Cyclin O CG
208915 s at ENSG00000103365 Golgi-associated, gamma adaptin ear con-
taining, ARF binding protein 2
IPT
Position 2 214318 s at ENSG00000073910 Furry homolog ACC
Position 3 205766 at ENSG00000173991 Titin-cap (Telethonin) ACC
221696 s at ENSG00000060140 Serine/threonine/tyrosine kinase 1 CG
202498 s at ENSG00000059804 Solute carrier family 2 (facilitated glucose
transporter), member 3
STM
Position 2 201102 s at ENSG00000141959 Phosphofructokinase, liver STM
Position 3 208915 s at ENSG00000103365 Golgi-associated, gamma adaptin ear con-
taining, ARF binding protein 2
IPT
Position 2 201316 at ENSG00000106588 Proteasome (prosome, macropain) subunit,
alpha type, 2
APC
Position 3 212288 at ENSG00000187239 Formin binding protein 1 ACC
Position 2 209713 s at ENSG00000116704 Solute carrier family 35 (UDP-GlcA/UDP-
GalNAc transporter), member D1
STM
Position 3 208915 s at ENSG00000103365 Golgi-associated, gamma adaptin ear con-
taining, ARF binding protein 2
IPT
Position 2 212702 s at ENSG00000185963 Bicaudal D homolog 2 ACC
Position 3 221030 s at ENSG00000138639 Rho GTPase activating protein 24 ACC
Position 2 212956 at ENSG00000109436 TBC1 domain family, member 9 (with
GRAM domain)
IPT
Position 3 210221 at ENSG00000080644 Cholinergic receptor, nicotinic, alpha 3
(neuronal)
ITT
Position 2 214194 at ENSG00000083520 DIS3 mitotic control homolog (Ribosomal
RNA-processing protein 44)
TF
Position 3 221696 s at ENSG00000060140 Serine/threonine/tyrosine kinase 1 CG
Position 2 216814 at ENSG00000232267 ACTR3 pseudogene 2 PUP
Position 3 221103 s at ENSG00000206530 Cilia and flagella associated protein 44 ACC
Position 2 221030 s at ENSG00000138639 Rho GTPase activating protein 24 ACC
Position 3 201316 at ENSG00000106588 Proteasome (prosome, macropain) subunit,
alpha type, 2
APC
Position 2 221696 s at ENSG00000060140 Serine/threonine/tyrosine kinase 1 CG
Position 3 209287 s at ENSG00000070831 Cell division control protein 42 homolog ACC
Position 2 221901 at ENSG00000138944 KIAA1644 PUP
Position 3 208915 s at ENSG00000103365 Golgi-associated, gamma adaptin ear con-
taining, ARF binding protein 2
IPT
Position 1 209602 s at ENSG00000107485 GATA3 TF
Position 2 202951 at ENSG00000112079 Serine/threonine kinase 38 CG
Position 3 220443 s at ENSG00000116035 VAX2 (ventral anterior homeobox 2) TF
221955 at ENSG00000088256 Guanine nucleotide binding protein (G pro-
tein), alpha 11 (Gq class)
ITT
207303 at ENSG00000154678 Phosphodiesterase 1C, calmodulin-
dependent 70kDa
ST
205152 at ENSG00000157103 Solute carrier family 6, member 1 ST
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207518 at ENSG00000153933 Diacylglycerol kinase, epsilon 64kDa ST
Position 2 206270 at ENSG00000126583 Protein kinase C, gamma ST
Position 3 208964 s at ENSG00000149485 Fatty acid desaturase 1 FAM
201197 at ENSG00000123505 Adenosylmethionine decarboxylase 1 CG
201102 s at ENSG00000141959 ATP-dependent 6-phosphofructokinase,
liver type
STM
214972 at ENSG00000198408 Protein O-GlcNAcase (Meningioma ex-
pressed antigen 5 (hyaluronidase))
ST
Position 2 210477 x at ENSG00000107643 Mitogen-activated protein kinase 8 CG
Position 3 205907 s at ENSG00000127083 Osteomodulin STM
NETWORK 2
Position 1 212195 at ENSG00000134352 IL6 Signal Transducer ICT
Position 2 202951 at ENSG00000112079 Serine/threonine kinase 38 CG
Position 3 221955 at ENSG00000088256 Guanine nucleotide binding protein (G pro-
tein), alpha 11 (Gq class)
ITT
207303 at ENSG00000154678 Phosphodiesterase 1C, calmodulin-
dependent 70kDa
ICT
NETWORK 3
Position 1 212956 at ENSG00000109436 TBC1 domain family, member 9 (with
GRAM domain)
IPT
Position 2 202951 at ENSG00000112079 Serine/threonine kinase 38 CG
Position 3 205152 at ENSG00000157103 Solute carrier family 6, member 1 ST
207518 at ENSG00000153933 Diacylglycerol kinase, epsilon 64kDa ST
Position 2 216814 at ENSG00000232267 ACTR3 pseudogene 2 PUP
Position 3 221103 s at ENSG00000206530 Cilia and flagella associated protein 44 ACC
Table 3: Biomarker network organisation - breast cancer data set - Estrogen Receptor - Breast
Cancer.
TF = Transcription/translation factor activity, DNA/RNA repair and catabolism - ER = estrogen
receptor activity - APC = autophagy - protein catabolism - IR = immunity, inflammatory
response (blood coagulation, antigen presentation and complement activation) - CC = cell/cell
communication - ST = intracellular signal transduction, protein glycosylation - CG = cell
growth and division - IPT = intracellular protein trafficking , transmembrane amino-acid
transporter - ACC = actin activity, cytoskeleton organisation, cell projection - STM = sugar
transport and metabolism - ITT = ion transmembrane transport, transmembrane signaling
systems - PUP = pseudogene, uncharacterized protein - FAM = fatty acid metabolism. Source:
www. uniprot. org ; www. ncbi. nlm. nih. gov/ gene
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